* covid-19 infection positive patients (including suspected or asymptomatic cases); * have a history of sars and mers infection; * have been vaccinated by any covid-19 vaccines other than vero cell vaccine； * have an axillary temperature 37.3 (forehead temperature 37.8℃℃); * have had previous allergic reactions to vaccination (such as acute allergic reactions, urticaria, eczema, dyspnea, angioneurotic oedema or abdominal pain) or allergy to known components of covid-19 vaccine; * history of thrombocytopenia or other coagulation disorders; * patients with known immunological impairment or immunocompromised. * received whole blood, blood products, plasma and/or immunoglobulin therapy within 3 months before study enrollment * have known or suspected severe illness such as respiratory illness, acute infection or active attacks of chronic illness, liver and kidney disease, severe diabetes mellitus, malignant tumour, infectious or allergic skin disease, human immunodeficiency virus (hiv) infection (test report available); * diagnosed with serious cardiovascular diseases such as cardiopulmonary failure, drug-uncontrolled hypertension (systolic blood pressure 160 mmhg and/or diastolic blood pressure 95 mmhg). * received live attenuated vaccines within 1 month before study enrollment; * received inactivated vaccines within 14 days before study enrollment; * received other investigational drugs within 6 months before study enrollment; * other vaccination-related contraindications considered by investigators.

* covid-19 infection positive patients (including suspected or asymptomatic cases); * have a history of sars and mers infection; * have been vaccinated by any covid-19 vaccines other than vero cell vaccine； * have an axillary temperature 37.3 (forehead temperature 37.8℃℃); * have had previous allergic reactions to vaccination (such as acute allergic reactions, urticaria, eczema, dyspnea, angioneurotic oedema or abdominal pain) or allergy to known components of covid-19 vaccine; * history of thrombocytopenia or other coagulation disorders; * patients with known immunological impairment or immunocompromised. * received whole blood, blood products, plasma and/or immunoglobulin therapy within 3 months before study enrollment * have known or suspected severe illness such as respiratory illness, acute infection or active attacks of chronic illness, liver and kidney disease, severe diabetes mellitus, malignant tumour, infectious or allergic skin disease, human immunodeficiency virus (hiv) infection (test report available); * diagnosed with serious cardiovascular diseases such as cardiopulmonary failure, drug-uncontrolled hypertension (systolic blood pressure 160 mmhg and/or diastolic blood pressure 95 mmhg). * received live attenuated vaccines within 1 month before study enrollment; * received inactivated vaccines within 14 days before study enrollment; * received other investigational drugs within 6 months before study enrollment; * other vaccination-related contraindications considered by investigators.

covid-19 infection positive patients (including suspected or asymptomatic cases); have a history of sars and mers infection; have been vaccinated by any covid-19 vaccines other than vero cell vaccine； have an axillary temperature 37.3 (forehead temperature 37.8℃℃); have had previous allergic reactions to vaccination (such as acute allergic reactions, urticaria, eczema, dyspnea, angioneurotic oedema or abdominal pain) or allergy to known components of covid-19 vaccine; history of thrombocytopenia or other coagulation disorders; patients with known immunological impairment or immunocompromised. received whole blood, blood products, plasma and/or immunoglobulin therapy within 3 months before study enrollment have known or suspected severe illness such as respiratory illness, acute infection or active attacks of chronic illness, liver and kidney disease, severe diabetes mellitus, malignant tumour, infectious or allergic skin disease, human immunodeficiency virus (hiv) infection (test report available); diagnosed with serious cardiovascular diseases such as cardiopulmonary failure, drug-uncontrolled hypertension (systolic blood pressure 160 mmhg and/or diastolic blood pressure 95 mmhg). received live attenuated vaccines within 1 month before study enrollment; received inactivated vaccines within 14 days before study enrollment; received other investigational drugs within 6 months before study enrollment; other vaccination-related contraindications considered by investigators.

covid-19 infection positive patients (including suspected or asymptomatic cases); have a history of sars and mers infection; have been vaccinated by any covid-19 vaccines other than vero cell vaccine； have an axillary temperature 37.3 (forehead temperature 37.8℃℃); have had previous allergic reactions to vaccination (such as acute allergic reactions, urticaria, eczema, dyspnea, angioneurotic oedema or abdominal pain) or allergy to known components of covid-19 vaccine; history of thrombocytopenia or other coagulation disorders; patients with known immunological impairment or immunocompromised. received whole blood, blood products, plasma and/or immunoglobulin therapy within 3 months before study enrollment have known or suspected severe illness such as respiratory illness, acute infection or active attacks of chronic illness, liver and kidney disease, severe diabetes mellitus, malignant tumour, infectious or allergic skin disease, human immunodeficiency virus (hiv) infection (test report available); diagnosed with serious cardiovascular diseases such as cardiopulmonary failure, drug-uncontrolled hypertension (systolic blood pressure 160 mmhg and/or diastolic blood pressure 95 mmhg). received live attenuated vaccines within 1 month before study enrollment; received inactivated vaccines within 14 days before study enrollment; received other investigational drugs within 6 months before study enrollment; other vaccination-related contraindications considered by investigators.

confirmed cases, suspected cases or asymptomatic infection of covid-19; with a history of sars and mers infection (self-report, on-site inquiry); axillary temperature ≥ 37.3 ℃ (forehead temperature ≥ 37.8 ℃); previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain); allergy to known components of recombinant covid-19 vaccine (e.g., aluminum and histidine); severe respiratory diseases, severe liver and kidney diseases, hypertension (systolic blood pressure ≥ 150 mmhg, diastolic blood pressure ≥ 90 mmhg), diabetic complications, malignant tumors, various acute diseases or acute attacks of chronic diseases; has been diagnosed with congenital or acquired immunodeficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases; has a history of convulsions, epilepsy, encephalopathy, long-term alcohol and drug abuse, history of thyroidectomy, history of infectious diseases, mental illness or family history (direct); with congenital malformation or developmental disorder, genetic defect, severe malnutrition, etc.; has a history of coagulation dysfunction (e.g., coagulation factors deficiency and coagulation diseases); asplenia or splenectomy, functional asplenia caused by any situation; receiving anti-tb (tuberculosis) therapy; received immunoenhancement or inhibitor therapy within 3 months (continuous oral or intravenous administration for more than 14 days); received other vaccines within 14 days before vaccination; received blood products within 3 months before vaccination; received other investigational drugs within 6 months before vaccination; plans to move before the end of the study or leave the local area for a long time during the scheduled study visits; other circumstances judged by investigators that are not suitable for this clinical trial.

confirmed cases, suspected cases or asymptomatic infection of covid-19; with a history of sars and mers infection (self-report, on-site inquiry); axillary temperature ≥ 37.3 ℃ (forehead temperature ≥ 37.8 ℃); previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain); allergy to known components of recombinant covid-19 vaccine (e.g., aluminum and histidine); severe respiratory diseases, severe liver and kidney diseases, hypertension (systolic blood pressure ≥ 150 mmhg, diastolic blood pressure ≥ 90 mmhg), diabetic complications, malignant tumors, various acute diseases or acute attacks of chronic diseases; has been diagnosed with congenital or acquired immunodeficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases; has a history of convulsions, epilepsy, encephalopathy, long-term alcohol and drug abuse, history of thyroidectomy, history of infectious diseases, mental illness or family history (direct); with congenital malformation or developmental disorder, genetic defect, severe malnutrition, etc.; has a history of coagulation dysfunction (e.g., coagulation factors deficiency and coagulation diseases); asplenia or splenectomy, functional asplenia caused by any situation; receiving anti-tb (tuberculosis) therapy; received immunoenhancement or inhibitor therapy within 3 months (continuous oral or intravenous administration for more than 14 days); received other vaccines within 14 days before vaccination; received blood products within 3 months before vaccination; received other investigational drugs within 6 months before vaccination; plans to move before the end of the study or leave the local area for a long time during the scheduled study visits; other circumstances judged by investigators that are not suitable for this clinical trial.